Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Sanchorawala, Vaishali; Sun, Fangui; Quillen, Karen; Sloan, J Mark; Berk, John L; Seldin, David C

Sanchorawala, Vaishali; Sun, Fangui; Quillen, Karen; Sloan, J Mark; Berk, John L; Seldin, David C.

Afiliação

Sanchorawala V; Section of Hematology-Oncology and Amyloidosis Center, Boston University School of Medicine, Boston, MA.
Sun F; Amyloidosis Center, Boston University School of Medicine, and Department of Biostatistics, Boston University School of Public Health, Boston, MA.
Quillen K; Section of Hematology-Oncology and Amyloidosis Center, Boston University School of Medicine, Boston, MA.
Sloan JM; Section of Hematology-Oncology and Amyloidosis Center, Boston University School of Medicine, Boston, MA.
Berk JL; Amyloidosis Center, Boston University School of Medicine, Boston, MA.
Seldin DC; Section of Hematology-Oncology and Amyloidosis Center, Boston University School of Medicine, Boston, MA.

Blood ; 126(20): 2345-7, 2015 Nov 12.

Article em En | MEDLINE | ID: mdl-26443620

Assuntos

Amiloidose/mortalidade; Amiloidose/terapia; Melfalan/administração & dosagem; Transplante de Células-Tronco; Adulto; Idoso; Idoso de 80 Anos ou mais; Feminino; Seguimentos; Humanos; Masculino; Pessoa de Meia-Idade

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco / Amiloidose / Melfalan Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google